Formosa Pharmaceuticals Inc
Formosa Pharmaceuticals Inc is a pharmaceutical company that develops, produces, and markets generic and branded drugs, primarily in the Asia-Pacific region.
Business. Formosa Pharmaceuticals Inc (6838.TW) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Formosa Pharmaceuticals Inc (6838.TW) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Formosa Pharmaceuticals Inc has a current ratio of 4.58, indicating strong short-term liquidity, but its operating cash flow is negative at -53,728,000 TWD, and free cash flow is also negative at -9,433,000 TWD. The company's debt-to-equity ratio is 0.03, suggesting a conservative capital structure with minimal leverage.
The company's profitability is weak, with a return on equity of -1.76% and a return on assets of -1.12%, both significantly below the industry median for pharmaceutical companies. This underperformance is reflected in its net income of -19,471,000 TWD, despite a high gross profit of 111,825,000 TWD.
Formosa Pharmaceuticals Inc's revenue is concentrated in the Asia-Pacific region, with no disclosed segment breakdown in the latest financial data. The company's exposure to this region may pose risks due to regulatory changes or economic volatility.
The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the latest financial data. However, its operating income of 13,379,000 TWD suggests some level of operational efficiency.
The company faces liquidity risks due to its negative operating and free cash flows, despite a low debt-to-equity ratio. There is no indication of dilution risk in the near term, as shares outstanding remain unchanged between basic and diluted shares.
Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's financial performance and risk profile suggest a need for operational improvements to restore profitability and strengthen cash flow.
- Formosa Pharmaceuticals Inc has a strong current ratio but negative operating and free cash flows, indicating liquidity challenges.
- The company's return on equity and return on assets are negative, reflecting poor profitability.
- Revenue is concentrated in the Asia-Pacific region, which may expose the company to regional economic and regulatory risks.
- There is no immediate dilution risk, as basic and diluted shares are equal.
- The company's capital structure is conservative, with a low debt-to-equity ratio.
Bull / Bear case
Generated · model-assistedCash conversion ratio of 2.76 ranks as best-in-class, far surpassing the cohort median of 0.95 among 862 pharmaceutical companies.
Net income improved by 58.4% year-over-year, demonstrating a strong trajectory in reducing losses compared to the prior fiscal period.
Free cash flow improved by 54.5% year-over-year, suggesting enhanced liquidity generation despite ongoing operational challenges and negative absolute values.
Debt-to-equity ratio of 0.03 is well below the cohort median of 0.18, reflecting a conservative capital structure with minimal leverage risk.
The company recorded a negative gross profit of TWD 1.6 million in the latest period, meaning costs exceeded revenue directly.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Formosa Pharmaceuticals Inc Market data — financials · 2026-05-27